OTCMKTS:RSPI Cortex Pharmaceuticals (RSPI) Stock Price, News & Analysis $0.0018 0.00 (0.00%) As of 10/12/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Cortex Pharmaceuticals Stock (OTCMKTS:RSPI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cortex Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0018▼$0.001850-Day Range N/A52-Week Range$0.0001▼$0.0027VolumeN/AAverage VolumeN/AMarket Capitalization$1.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cortex Pharmaceuticals was a biotechnology company focused on developing therapies for central nervous system disorders. Its research centered on ampakines, a class of compounds designed to modulate AMPA receptors in the brain and potentially improve respiratory function, cognition, and other neurological processes. The company’s development programs included CX717 and related compounds investigated for conditions such as opioid-induced respiratory depression, attention-deficit/hyperactivity disorder, and cognitive impairment. Cortex pursued these programs through preclinical research and clinical trials, although several candidates faced regulatory and development challenges. Cortex Pharmaceuticals later changed its corporate name to RespireRx Pharmaceuticals, Inc. The company’s securities have been associated with the OTC Markets symbol RSPI. Publicly available information about its current operations, commercial products, geographic presence, and leadership is limited.AI Generated. May Contain Errors. Read More Receive RSPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cortex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RSPI Stock News HeadlinesRespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested PartiesNovember 20, 2025 | globenewswire.comRespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License AgreementNovember 19, 2025 | globenewswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 13 at 1:00 AM | Altimetry (Ad)RespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common StockNovember 18, 2025 | markets.businessinsider.comRespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, ...February 10, 2025 | gurufocus.comRespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord InjuryMay 29, 2024 | globenewswire.comRespireRx Pharmaceuticals Inc (RSPI)May 23, 2024 | investing.comRespireRx Pharmaceuticals Inc RSPIMay 1, 2024 | morningstar.comMSee More Headlines RSPI Stock Analysis - Frequently Asked Questions How have RSPI shares performed this year? Cortex Pharmaceuticals' stock was trading at $0.0018 at the beginning of 2026. Since then, RSPI stock has increased by 0.0% and is now trading at $0.0018. How were Cortex Pharmaceuticals' earnings last quarter? Cortex Pharmaceuticals Inc. (OTCMKTS:RSPI) posted its quarterly earnings results on Wednesday, August, 19th. The company reported ($0.01) EPS for the quarter. How do I buy shares of Cortex Pharmaceuticals? Shares of RSPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cortex Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cortex Pharmaceuticals investors own include Galaxy Next Generation (GAXY), American Coastal Insurance (ACIC), Appian (APPN), Aquestive Therapeutics (AQST), Arrowhead Pharmaceuticals (ARWR), AMC Entertainment (AMC) and Arista Networks (ANET). Company Calendar Last Earnings8/19/2020Today10/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:RSPI CIK849636 Webwww.respirerx.com Phone(201) 444-4947Fax949-727-3657Employees2Year Founded1988Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares949,460,000Free Float474,447,000Market Cap$1.71 million OptionableNot Optionable BetaN/A 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:RSPI) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortex Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortex Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RSPI Stock Alerts